Drug intelligence / Profile preview

TRX-214

Development stage: Preclinical
Lead developer: Therapex
Modality: PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
Administration: Intravenous

Overview

TRX-214 is a preclinical-stage degrader-antibody conjugate (DAC) being developed by Therapex for the treatment of solid tumors. As a DAC, the molecule combines the targeting specificity of a monoclonal antibody with the potent protein-clearing capability of a targeted protein degrader (TPD) payload. This modality is designed to overcome limitations of traditional antibody-drug conjugates (ADCs) by utilizing catalytic degradation of intracellular targets rather than stoichiometric killing. The specific antigen target and degrader mechanism for TRX-214 remain undisclosed by the developer.

Targets

CD33 (Myeloid cell surface antigen CD33)GSPT1 (G1 to S phase transition 1)

Beyond the preview

Go deeper on TRX-214.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TRX-214.